Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.50 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512547 | 0.90 | BACE1 (0.51) | BACE1VIPR2VIPR1GRIN2DGRIN3B | |
| SCHEMBL31346757 | 0.89 | BACE1 (0.55) | BACE1VIPR2VIPR1GRIN2DGRIN3B | |
| SCHEMBL30512610 | 0.89 | BACE1 (0.55) | BACE1VIPR2VIPR1GRIN2DGRIN3B | |
| SCHEMBL10700927 | 0.89 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL10700917 | 0.89 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL30182817 | 0.88 | BACE1 (0.58) | BACE1VIPR2VIPR1GRIN2DGRIN3B | |
| SCHEMBL31614422 | 0.87 | BACE1 (0.52) | BACE1VIPR2VIPR1GRIN2DGRIN3B | |
| SCHEMBL30512778 | 0.87 | GRIN2D (0.56) | BACE1VIPR2VIPR1GRIN2DGRIN3B | |
| SCHEMBL29679673 | 0.87 | GRIN2D (0.51) | VIPR2VIPR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL29453346 | 0.87 | BACE1 (0.56) | BACE1VIPR2VIPR1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177373-A1 | COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION | THE CHILDEREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4554628-A1 | HIV IMMUNOGENIC POLYPEPTIDES AND VACCINES AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-115010805-B | HIV-1 GP41 neutralizing antibodies and uses thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2025-01-28 | — | — | CN | disclosed |
| US-20240366738-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES INC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024220982-A1 | COMPOSITIONS COMPRISING APTAMERS AND METHODS OF MODULATING THE IMMUNE RESPONSE USING THE SAME | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-10-24 | — | — | WO | disclosed |
| US-12064425-B2 | Compositions and methods for targeting a viral infection | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2024-08-20 | — | — | US | disclosed |
| CN-114478796-B | Modified human immunodeficiency virus membrane proteins and uses thereof | 厦门大学 | 2024-08-06 | — | — | CN | disclosed |
| US-11992518-B2 | Molecular vaccines for infectious disease | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-111108116-B | Retroviral vectors | 牛津遗传学有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-110087679-B | Virus-like particles with high density coating for inducing antibody expression | 艾滋基金研究所 | 2024-03-22 | — | — | CN | disclosed |
| CN-117500931-A | measles-HIV or measles-HTLV vaccine | 维洛克塞斯 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024015741-A1 | HIV IMMUNOGENIC POLYPEPTIDES AND VACCINES AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-116171165-A | HIV-1 antibodies | 墨尔本大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-115010805-A | HIV-1 GP41 neutralizing antibodies and uses thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2022-09-06 | — | — | CN | disclosed |
| CN-107375919-B | Methods and compositions for antiviral immunization | 台湾地区“中央研究院” | 2022-07-29 | — | — | CN | disclosed |
| CN-108884149-B | HIV-1 GP41 neutralizing antibodies and uses thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2022-07-01 | — | — | CN | disclosed |
| CN-114478796-A | Modified human immunodeficiency virus membrane protein and application thereof | 厦门大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-108137676-B | gp120 neutralizing antibodies and uses thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177373-A1 | COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION | HAVCR2, CD4, MAVS | BACE1 653/4885VIPR2 2337/4885VIPR1 797/4885 |
| US-12064425-B2 | Compositions and methods for targeting a viral infection | HAVCR2, CD4, MAVS | BACE1 653/4885VIPR2 2337/4885VIPR1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.